RAD18 and colorectal carcinoma: Based on the observation that Rad18 is actually highly expressed in 5-FU-resistant CRC cells, miR-145 could play a significant role in debilitating the DNA damage response through its inhibitory effect on Rad18 and counteracting drug resistance in cancer cells [145].